Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 283 entries
Sorted by: Best Match Show Resources per page
Erratum to: Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).

CNS drugs

Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB.
PMID: 28451963
CNS Drugs. 2017 Jun;31(6):511. doi: 10.1007/s40263-017-0435-y.

No abstract available.

Cite
Keyloun KR, Hansen RN, Hepp Z, et al. Erratum to: Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs. 2017;31(6):511doi: 10.1007/s40263-017-0435-y.
Keyloun, K. R., Hansen, R. N., Hepp, Z., Gillard, P., Thase, M. E., & Devine, E. B. (2017). Erratum to: Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS drugs, 31(6), 511. https://doi.org/10.1007/s40263-017-0435-y
Keyloun, Katelyn R, et al. "Erratum to: Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)." CNS drugs vol. 31,6 (2017): 511. doi: https://doi.org/10.1007/s40263-017-0435-y
Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB. Erratum to: Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs. 2017 Jun;31(6):511. doi: 10.1007/s40263-017-0435-y. PMID: 28451963; PMCID: PMC6828180.
Copy Download .nbib Format: NLM
Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.

CNS drugs

Pariente G, Leibson T, Shulman T, Adams-Webber T, Barzilay E, Nulman I.
PMID: 28512694
CNS Drugs. 2017 Jun;31(6):451. doi: 10.1007/s40263-017-0439-7.

No abstract available.

Cite
Pariente G, Leibson T, Shulman T, et al. Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. CNS Drugs. 2017;31(6):451doi: 10.1007/s40263-017-0439-7.
Pariente, G., Leibson, T., Shulman, T., Adams-Webber, T., Barzilay, E., & Nulman, I. (2017). Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. CNS drugs, 31(6), 451. https://doi.org/10.1007/s40263-017-0439-7
Pariente, Gali, et al. "Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis." CNS drugs vol. 31,6 (2017): 451. doi: https://doi.org/10.1007/s40263-017-0439-7
Pariente G, Leibson T, Shulman T, Adams-Webber T, Barzilay E, Nulman I. Erratum to: Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. CNS Drugs. 2017 Jun;31(6):451. doi: 10.1007/s40263-017-0439-7. PMID: 28512694.
Copy Download .nbib Format: NLM
Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries.

Organic letters

Fan Z, Li J, Lu H, Wang DY, Wang C, Uchiyama M, Zhang A.
PMID: 28574271
Org Lett. 2017 Jun 16;19(12):3199-3202. doi: 10.1021/acs.orglett.7b01297. Epub 2017 Jun 02.

A removable oxime-assisted meta-C-H nitration of arenes is reported. Mechanistic investigations and DFT calculations reveal a new monomeric octahedral ruthenium(II) complex is responsible for the meta-selective nitration. Dioxygen as a cooxidant is crucial for achieving high conversion and good...

Cite
Fan Z, Li J, Lu H, et al. Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries. Org Lett. 2017;19(12):3199-3202doi: 10.1021/acs.orglett.7b01297.
Fan, Z., Li, J., Lu, H., Wang, D. Y., Wang, C., Uchiyama, M., & Zhang, A. (2017). Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries. Organic letters, 19(12), 3199-3202. https://doi.org/10.1021/acs.orglett.7b01297
Fan, Zhoulong, et al. "Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries." Organic letters vol. 19,12 (2017): 3199-3202. doi: https://doi.org/10.1021/acs.orglett.7b01297
Fan Z, Li J, Lu H, Wang DY, Wang C, Uchiyama M, Zhang A. Monomeric Octahedral Ruthenium(II) Complex Enabled meta-C-H Nitration of Arenes with Removable Auxiliaries. Org Lett. 2017 Jun 16;19(12):3199-3202. doi: 10.1021/acs.orglett.7b01297. Epub 2017 Jun 02. PMID: 28574271.
Copy Download .nbib Format: NLM
Histamine and Seizures : Implications for the Treatment of Epilepsy.

CNS drugs

Yokoyama H, Iinuma K.
PMID: 26071045
CNS Drugs. 1996 May;5(5):321-30. doi: 10.2165/00023210-199605050-00002.

Experimental studies have indicated that the central histaminergic neuron system plays an important role in the inhibition of seizures through stimulation of histamine H1 receptors, especially in the developmental period. This has therapeutic implications for currently available drugs that...

Cite
Yokoyama H, Iinuma K. Histamine and Seizures : Implications for the Treatment of Epilepsy. CNS Drugs. 1996;5(5):321-30doi: 10.2165/00023210-199605050-00002.
Yokoyama, H., & Iinuma, K. (1996). Histamine and Seizures : Implications for the Treatment of Epilepsy. CNS drugs, 5(5), 321-30. https://doi.org/10.2165/00023210-199605050-00002
Yokoyama, H, and Iinuma, K. "Histamine and Seizures : Implications for the Treatment of Epilepsy." CNS drugs vol. 5,5 (1996): 321-30. doi: https://doi.org/10.2165/00023210-199605050-00002
Yokoyama H, Iinuma K. Histamine and Seizures : Implications for the Treatment of Epilepsy. CNS Drugs. 1996 May;5(5):321-30. doi: 10.2165/00023210-199605050-00002. PMID: 26071045.
Copy Download .nbib Format: NLM
Erratum to: Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome.

CNS drugs

Frampton JE.
PMID: 26293746
CNS Drugs. 2015 Aug;29(8):713. doi: 10.1007/s40263-015-0274-7.

No abstract available.

Cite
Frampton JE. Erratum to: Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome. CNS Drugs. 2015;29(8):713doi: 10.1007/s40263-015-0274-7.
Frampton, J. E. (2015). Erratum to: Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome. CNS drugs, 29(8), 713. https://doi.org/10.1007/s40263-015-0274-7
Frampton, James E. "Erratum to: Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome." CNS drugs vol. 29,8 (2015): 713. doi: https://doi.org/10.1007/s40263-015-0274-7
Frampton JE. Erratum to: Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome. CNS Drugs. 2015 Aug;29(8):713. doi: 10.1007/s40263-015-0274-7. PMID: 26293746.
Copy Download .nbib Format: NLM
Problems in the Assessment of Potential Antiepileptic Drugs.

CNS drugs

Eadie MJ.
PMID: 27520515
CNS Drugs. 1994 Mar;1(3):167-71. doi: 10.2165/00023210-199401030-00001.

Epilepsy is a serious and common neurological disorder for which effective and well tolerated new agents continue to be sought. While the assessment of potential antiepileptic agents in animals models of epilepsy poses few problems, such assessment in humans...

Cite
Eadie MJ. Problems in the Assessment of Potential Antiepileptic Drugs. CNS Drugs. 1994;1(3):167-71doi: 10.2165/00023210-199401030-00001.
Eadie, M. J. (1994). Problems in the Assessment of Potential Antiepileptic Drugs. CNS drugs, 1(3), 167-71. https://doi.org/10.2165/00023210-199401030-00001
Eadie, M J. "Problems in the Assessment of Potential Antiepileptic Drugs." CNS drugs vol. 1,3 (1994): 167-71. doi: https://doi.org/10.2165/00023210-199401030-00001
Eadie MJ. Problems in the Assessment of Potential Antiepileptic Drugs. CNS Drugs. 1994 Mar;1(3):167-71. doi: 10.2165/00023210-199401030-00001. PMID: 27520515.
Copy Download .nbib Format: NLM
The Fluoxetine and Suicide Controversy : A Review of the Evidence.

CNS drugs

Healy D.
PMID: 27520521
CNS Drugs. 1994 Mar;1(3):223-31. doi: 10.2165/00023210-199401030-00007.

Evidence is emerging that a range of psychotropic drugs may precipitate akathisia and/or panic reactions in predisposed patients. The use of fluoxetine has hitherto been the most notable example of this occurrence. These reactions may foster the genesis of...

Cite
Healy D. The Fluoxetine and Suicide Controversy : A Review of the Evidence. CNS Drugs. 1994;1(3):223-31doi: 10.2165/00023210-199401030-00007.
Healy, D. (1994). The Fluoxetine and Suicide Controversy : A Review of the Evidence. CNS drugs, 1(3), 223-31. https://doi.org/10.2165/00023210-199401030-00007
Healy, D. "The Fluoxetine and Suicide Controversy : A Review of the Evidence." CNS drugs vol. 1,3 (1994): 223-31. doi: https://doi.org/10.2165/00023210-199401030-00007
Healy D. The Fluoxetine and Suicide Controversy : A Review of the Evidence. CNS Drugs. 1994 Mar;1(3):223-31. doi: 10.2165/00023210-199401030-00007. PMID: 27520521.
Copy Download .nbib Format: NLM
Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

CNS drugs

Soyka M.
PMID: 27520754
CNS Drugs. 1997 Apr;7(4):313-27. doi: 10.2165/00023210-199707040-00004.

Most psychotropic drugs, such as antipsychotics, lithium and tricyclic antidepressants, do not improve alcohol (ethanol) abstinence rates, at least in alcohol-dependent patients who do not have a comorbid psychiatric disorder. In recent years, numerous studies have been published that...

Cite
Soyka M. Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS Drugs. 1997;7(4):313-27doi: 10.2165/00023210-199707040-00004.
Soyka, M. (1997). Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS drugs, 7(4), 313-27. https://doi.org/10.2165/00023210-199707040-00004
Soyka, M. "Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities." CNS drugs vol. 7,4 (1997): 313-27. doi: https://doi.org/10.2165/00023210-199707040-00004
Soyka M. Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS Drugs. 1997 Apr;7(4):313-27. doi: 10.2165/00023210-199707040-00004. PMID: 27520754.
Copy Download .nbib Format: NLM
Mixed Anxiety and Depression : Diagnosis and Treatment Options.

CNS drugs

Bakish D, Habib R, Hooper CL.
PMID: 27521010
CNS Drugs. 1998 Apr;9(4):271-80. doi: 10.2165/00023210-199809040-00003.

Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational...

Cite
Bakish D, Habib R, Hooper CL. Mixed Anxiety and Depression : Diagnosis and Treatment Options. CNS Drugs. 1998;9(4):271-80doi: 10.2165/00023210-199809040-00003.
Bakish, D., Habib, R., & Hooper, C. L. (1998). Mixed Anxiety and Depression : Diagnosis and Treatment Options. CNS drugs, 9(4), 271-80. https://doi.org/10.2165/00023210-199809040-00003
Bakish, D, et al. "Mixed Anxiety and Depression : Diagnosis and Treatment Options." CNS drugs vol. 9,4 (1998): 271-80. doi: https://doi.org/10.2165/00023210-199809040-00003
Bakish D, Habib R, Hooper CL. Mixed Anxiety and Depression : Diagnosis and Treatment Options. CNS Drugs. 1998 Apr;9(4):271-80. doi: 10.2165/00023210-199809040-00003. PMID: 27521010.
Copy Download .nbib Format: NLM
CNS Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs : Therapeutic Implications.

CNS drugs

Morgan A, Clark D.
PMID: 27521013
CNS Drugs. 1998 Apr;9(4):281-90. doi: 10.2165/00023210-199809040-00004.

It is difficult to obtain valid estimations of the true incidence of CNS effects associated with nonsteroidal anti-inflammatory drugs (NSAIDs) from spontaneously reported adverse reactions. This is because the reporting rates of adverse reactions are low and the total...

Cite
Morgan A, Clark D. CNS Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs : Therapeutic Implications. CNS Drugs. 1998;9(4):281-90doi: 10.2165/00023210-199809040-00004.
Morgan, A., & Clark, D. (1998). CNS Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs : Therapeutic Implications. CNS drugs, 9(4), 281-90. https://doi.org/10.2165/00023210-199809040-00004
Morgan, A, and Clark, D. "CNS Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs : Therapeutic Implications." CNS drugs vol. 9,4 (1998): 281-90. doi: https://doi.org/10.2165/00023210-199809040-00004
Morgan A, Clark D. CNS Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs : Therapeutic Implications. CNS Drugs. 1998 Apr;9(4):281-90. doi: 10.2165/00023210-199809040-00004. PMID: 27521013.
Copy Download .nbib Format: NLM
Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs.

ACS medicinal chemistry letters

Gunaydin H.
PMID: 26819672
ACS Med Chem Lett. 2015 Dec 02;7(1):89-93. doi: 10.1021/acsmedchemlett.5b00390. eCollection 2016 Jan 14.

Multiparameter optimization (MPO) scoring functions are popular tools for providing guidance on how to design desired molecules in medicinal chemistry. The utility of a new probabilistic MPO (pMPO) scoring function method and its application as a scoring function for...

Cite
Gunaydin H. Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs. ACS Med Chem Lett. 2015;7(1):89-93doi: 10.1021/acsmedchemlett.5b00390.
Gunaydin, H. (2016). Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs. ACS medicinal chemistry letters, 7(1), 89-93. https://doi.org/10.1021/acsmedchemlett.5b00390
Gunaydin, Hakan. "Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs." ACS medicinal chemistry letters vol. 7,1 (2016): 89-93. doi: https://doi.org/10.1021/acsmedchemlett.5b00390
Gunaydin H. Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs. ACS Med Chem Lett. 2015 Dec 02;7(1):89-93. doi: 10.1021/acsmedchemlett.5b00390. eCollection 2016 Jan 14. PMID: 26819672; PMCID: PMC4716604.
Copy Download .nbib Format: NLM
Prevention of schizophrenia: can it be achieved?.

CNS drugs

Lee C, McGlashan TH, Woods SW.
PMID: 15740175
CNS Drugs. 2005;19(3):193-206. doi: 10.2165/00023210-200519030-00002.

Schizophrenia is a serious mental disorder with a profound impact on patients, their caregivers and society. It is also an expensive disorder to treat, despite being relatively rare. In this paper, prevention of schizophrenia is described in terms of...

Cite
Lee C, McGlashan TH, Woods SW. Prevention of schizophrenia: can it be achieved?. CNS Drugs. 2005;19(3):193-206doi: 10.2165/00023210-200519030-00002.
Lee, C., McGlashan, T. H., & Woods, S. W. (2005). Prevention of schizophrenia: can it be achieved?. CNS drugs, 19(3), 193-206. https://doi.org/10.2165/00023210-200519030-00002
Lee, Cheng, et al. "Prevention of schizophrenia: can it be achieved?." CNS drugs vol. 19,3 (2005): 193-206. doi: https://doi.org/10.2165/00023210-200519030-00002
Lee C, McGlashan TH, Woods SW. Prevention of schizophrenia: can it be achieved?. CNS Drugs. 2005;19(3):193-206. doi: 10.2165/00023210-200519030-00002. PMID: 15740175.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 283 entries